source
- FDA approves Takeda’s orexin receptor agonist for narcolepsy, opening new drug classThe FDA has granted approval to Takeda's novel narcolepsy medication, the first orexin receptor agonist to receive clearance. The twice‑daily pill, marketed as Orzeyful, is indicated for narcoleps…
- Novo Nordisk looks to bolt-on acquisitions as pipeline setbacks mountNovo Nordisk CEO Maziar Mike Doustdar said on a media call that the pharma industry is tough for those who dislike setbacks and failure. He highlighted recent disappointments in the company's pipe…